Compare Amphastar Pharmaceuticals Inc (AMPH) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Ross Stores, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.44 (market cap $826.08M), while Ross Stores, Inc. trades at $220.4 (market cap $71.50B). The key difference: Ross Stores, Inc. is far larger — about 86.6× Amphastar Pharmaceuticals Inc's market cap, and Ross Stores, Inc. pays a 0.8% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | ROST | |
|---|---|---|
Market Cap | $826.08M | $71.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $240.13 |
52-Week Low | $16.87 | $127.59 |
Enterprise Value | $1.22B | $72.09B |
Dividend Yield | — | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Ross Stores (ROST) trades at $222.88, up 1.02% with strong momentum near recent highs. The stock shows bullish technical signals with consistent earnings beats in recent quarters (Q3 2025-Q1 2026) and robust fundamentals including 38.98% ROE and 9.74% net margin. Revenue growth accelerated to $21.13B in 2025, with analyst consensus strongly favoring Buy ratings (63.83%) and a $259 price target representing 16% upside potential.
Outlook remains positive given strong operational execution and consumer demand, though valuation multiples (P/E 31.13) appear elevated. Key risks include retail sector competition and economic sensitivity. Institutional sentiment supports further gains if earnings momentum continues through Q2 2026 results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
